Relapse-associated worsening (RAW) Clinical progression in MS patients attributable to recurrent inflammatory attacks targeting various regions of the CNS, and inducing bystander damage to axons, myelin and glia
A significant concern is that the most common adverse effects of GLP-1 agonistsnausea, vomiting, diarrhea, and abdominal painoverlap substantially with Crohn's disease symptoms
At our clinic, the joint pain patients who see the most benefit from BPC-157 are those with chronic knee, shoulder, or hip pain that has plateaued after standard orthopedic treatment, particularly where inflammatory load is a significant component of the symptom picture
Actavis rejected the per se approach but held that these agreements could violate antitrust law and should be evaluated under the rule of reason [24]
In this study, we aimed to assess the risk of SIS in new users of GLP-1RA to treat type 2 diabetes mellitus in individuals with obesity, when compared with new users of sodium-glucose cotransporter 2 inhibitors (SGLT-2i)